Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  muromonab-CD3
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 27 for your search:
Start Over
Phase III Study of Adjuvant Autolymphocyte Therapy for T1-3 N1-3 M0 or T4 N0-3 M0 Renal Cell Carcinoma (Summary Last Modified 12/93)
Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: CUCCC-90-C01, NCI-V91-0009
Phase I/II Study of Activated Cytotoxic T Cells and Low-Dose Continuous-Infusion Interleukin-2 in Advanced Cancers (Summary Last Modified 09/98)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: STLMC-BRM-9502, NCI-V95-0764
Phase I/II Study of an Anti-T3 MoAb (OKT3) in Patients with Lymphoproliferative Disorders Bearing the T3 Antigen (Summary Last Modified 03/90)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: BRMP-8707B, NCI-87-C-99B, NCI-T87-0175N, T87-0175
Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Other
Protocol IDs: E203/2004, IRB Project Nr. 21/2004, HSZ-001, NCT00202917
Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067241, P30CA022453, WSU-C-1403-ME, NCI-G99-1565, NCT00004022
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067243, P30CA022453, WSU-C-1403-BT, NCI-G99-1567, NCT00004024
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
Phase: Phase II
Type: Treatment
Status: Completed
Age: 2 to 21
Sponsor: Other
Protocol IDs: HAPREF, NCT00143559
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 45 and under
Sponsor: NCI, Other
Protocol IDs: 1965.00, R01AI053193, P30CA015704, FHCRC-1965.00, CDR0000533834, 6428, NCT00450983
Lymphocyte Therapy in Treating Patients With Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 16
Sponsor: NCI
Protocol IDs: CDR0000063744, STLMC-BRM-9401, NCI-V94-0514, NCT00002589
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 040152, 04-C-0152, NCT00080353
Phase I Pilot Study of MOAB OKT3 in Patients with T-Cell (CD3+) Malignancies (Summary Last Modified 05/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CRB-9404, NCI-T93-0197N, T93-0197
Phase I Study of In Vitro Anti-CD3-Stimulated CD4+ T-Cell Subsets Given in Combination with Systemic IL-2 and CTX in Patients with Advanced Malignancies (Summary Last Modified 06/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-96-C-0134, CRB-9302, NCI-T93-0171N, T93-0171
Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: 93-0426.cc, UCHSC-COMIRB-93426, NCI-T94-0065O, T94-0065, NCT00002572
Phase IB Study of Anti-CD3 MOAB OKT3 plus IL-2 for Advanced Melanoma and Renal Cell Carcinoma (Summary Last Modified 08/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-96-C-0131, CRB-9207, NCI-T94-0083N, T94-0083
Phase I Study of Anti-CD3 Monoclonal Antibodies in Patients with Advanced Cancer (Summary Last Modified 04/90)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BRMP-8805B, NCI-89-C-44B, NCI-T88-0269N, T88-0269
Phase I Pilot Study of Chemoimmunotherapy with OKT3, TNF, and IL-2 in Patients with Unresectable or Metastatic (Stage IIIB or IV) non-Small Cell Lung Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 15
Sponsor: NCI
Protocol IDs: MDA-ID-88024, NCI-T88-0268D, T88-0268
Phase I/IB Study of the Murine Anti-CD3 Monoclonal Antibody OKT3 and IL-2 for Immune Activation in Patients with Cancer with Assessment of the Effect of Pentoxifylline on Toxicity and Immune Effect
Phase: Phase I
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: WCCC-CO-8991, NCI-B89-0004, B89-0004
Phase I/IB Study of MOAB OKT 3 plus IL-2 in Patients with Advanced non-T-Cell Malignancies (Summary Last Modified 01/94)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: LUMC-T90-0044, NCI-T90-0044O, T90-0044
Phase I Study of Killer Cells Activated In Vitro with MOAB OKT 3 and Administered in Combination with Systemic IL-2 or IL-2/CTX in Patients with Advanced Malignancies (Summary Last Modified 06/93)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BRMP-8920H, NCI-90-C-128H, NCI-T90-0017N, T90-0017
Phase I Study of Adoptive Cellular Therapy with Tumor-Primed Anti-CD3-Activated Lymphocytes in Patients with Metastatic Renal Cell Carcinoma
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CCUM-9018, NCI-T90-0148D, T90-0148
Start Over